Apogee Therapeutics, Inc. (APGE) - Stock Analysis
Last updated: Mar 22, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Apogee has multiple imminent clinical catalysts (APEX Phase 2 Part B 16‑week topline in Q2 2026 and Phase 3 AD start H2 2026) on top of strong 52‑week APEX Part A durability data released 2026‑03‑23 and a ~$350m equity raise at $70 that extends cash runway into 2028; with 21‑day ROC ~+10.8% and price ~9% above its 21‑day SMA, the setup is a classic event‑driven biotech hot idea.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Very high liquidity • Zero revenue • High cash burn APGE's balance sheet is extremely strong and low‑leverage (large cash/investments, minimal liabilities), but zero revenue, heavy operating losses and negative free cash flow leaving it dependent on financing create a high downside/speculative investment case.
Price Behavior
Key Price Behavior Insights: • Below SMA • Falling momentum • High‑60s support Support Level: $66.00–$68.50 Resistance Level: $75.00 (mid‑$70s); $80.00–$82.00 APGE is in a short-term downtrend—closing at $66.04 well below last month's SMA (~$70.90), with weakening momentum and immediate support around the high‑$60s that, if broken below $66.00, would expose further downside toward prior resistance only back in the mid‑$70s and $80–$82.
Sentiment & News
Key News Insights: • Institutional buying • Upcoming readouts • Strong cash runway Apogee is seeing heavy institutional buying alongside well-funded clinical progress—upcoming Phase 2/3 readouts and conference activity, backed by a $902.9M cash runway into H2 2028, have driven recent stock rallies.
AI Summary
APGE has shifted from a binary clinical-stage gamble to a de‑risked, event-driven investment—backed by >$900M cash and heavy institutional accumulation that make upcoming mid‑stage readouts value-creation checkpoints rather than existential tests, but investors must monitor clinical outcomes and burn/timing risk that could still force dilution if setbacks or delays accumulate.
Description
Apogee Therapeutics is a biotechnology firm developing biologic therapies for atopic dermatitis, COPD and related inflammatory and immunological conditions. Its lead programs are subcutaneously administered, extended half-life monoclonal antibodies advancing in AD and COPD, with additional earlier-stage antibody programs for AD. The company was founded in 2022 and is headquartered in Waltham, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 26 | Apr 2 | APGE | Apogee Therapeutics, Inc. | Apogee has multiple imminent clinical catalysts (APEX Phase 2 Part B 16‑week topline in Q2 2026 and Phase 3 AD start H2 2026) on top of strong 52‑week APEX Part A durability data released 2026‑03‑23 and a ~$350m equity raise at $70 that extends cash runway into 2028; with 21‑day ROC ~+10.8% and price ~9% above its 21‑day SMA, the setup is a classic event‑driven biotech hot idea. | Active | +0.0% |